Cold chain and stock handling for aesthetic clinics: a practical pharmacy guide

Most clinical complaints traced back to a product issue turn out, on investigation, to be storage failures.

Cold chain compliance is not a bureaucratic box to tick. For aesthetic clinics handling temperature-sensitive injectables, it is the single most controllable variable between a product performing as expected and one that does not. This guide covers what a compliant cold chain looks like from the moment you place an order to the moment you use the last vial, written for licensed UK practitioners managing their own clinical stock.

What cold chain means and which products need it

A cold chain is an unbroken sequence of temperature-controlled storage and transport that preserves a product from the point of manufacture to the point of use. Break the chain at any point and you may not know it until a patient has a suboptimal outcome or you receive a GPhC inspection finding.

In the aesthetic injectable category, the products most commonly requiring refrigerated storage (typically 2 to 8 degrees Celsius) include botulinum toxin products, certain hyaluronic acid fillers once reconstituted or opened, and a growing number of polynucleotide and biostimulator preparations. Always consult the manufacturer Instructions for Use (IFU) for the specific product in your clinic: the IFU is the legal primary source for storage requirements and overrides any general guidance, including this article.

Some fillers are stored at room temperature prior to opening but require refrigeration once a cartridge has been breached. Others are stable at controlled room temperature throughout their shelf life. Knowing the difference for every product on your formulary is a foundational clinical responsibility. Browse the full product range and check each product listing for storage information supplied by the manufacturer.

The right equipment: pharmacy-grade fridge versus domestic

A domestic fridge is not an acceptable storage unit for clinical injectables. This is not a matter of preference; it is a GDP and GPhC requirement. Here is why domestic units fail:

• Temperature fluctuation: domestic fridges cycle between 1 and 10 degrees Celsius or wider, especially near the door and fan outlet.
• No alarm function: there is no alert if the temperature drops below 2 degrees or rises above 8 degrees overnight.
• No validated temperature logging: you cannot demonstrate continuous compliance to an inspector.
• Cross-contamination risk: food and clinical products must not share storage.
• Inconsistent humidity control: condensation cycles can damage labelling and packaging integrity.

Purpose-built medical refrigerators from manufacturers such as Labcold and Lec Medical are designed to maintain a stable 2 to 8 degrees Celsius range with minimal cycling, include audible and visual alarms for excursions, and provide a physical or digital temperature log. For a small clinic, a Labcold pharmacy series unit (available in under-counter and full-height formats) or the Lec Medical PEGC series provides the right balance of capacity, alarm functionality, and cost.

Key features to look for when selecting a medical fridge:

Temperature monitoring: do not rely on a basic thermometer

A min/max thermometer tells you the range since it was last reset. It tells you nothing about when an excursion happened, how long it lasted, or whether it correlated with a delivery or a power interruption. For a clinic holding meaningful stock, a continuous data logger is the practical standard.

Devices such as the Sensaphone range allow remote temperature monitoring with SMS and email alerts, meaning you are notified of an excursion outside clinic hours before it becomes a full stock loss. Connect the logger to an uninterruptible power supply (UPS) if your fridge is not already on one.

Check your logger calibration annually and after any suspected equipment fault. Keep calibration records on file: a GPhC inspector or MHRA GDP auditor may ask to see them. GDP guidance from MHRA Good Distribution Practice sets out the documentation standards that apply to wholesale and supply chains; even clinics that do not hold a wholesale dealer licence benefit from operating to these principles.

Receiving a cold-chain delivery: what to check on arrival

The delivery moment is a documented transfer of responsibility. Treat it that way. Do not accept a delivery if no authorised person is present to receive it correctly.

Cold-chain delivery checklist:

• Check the outer packaging for damage, moisture ingress, or signs of having been opened.
• Check the temperature indicator or cold-pack status inside the insulated box. Most compliant pharmaceutical suppliers include a temperature indicator strip or a data logger printout.
• Compare the invoice or delivery note against your order: product name, batch number, expiry date, and quantity.
• Record the time of receipt and the ambient fridge temperature at the moment of transfer.
• Transfer products to the fridge immediately. Do not leave cold-chain items at room temperature while you process paperwork.
• Segregate any product with broken seals, missing documentation, or a triggered temperature indicator immediately and do not use it until you have assessed the excursion.
• File the delivery note and batch record in your stock management system.

If your supplier cannot provide evidence of temperature-controlled delivery for cold-chain products, that is a supplier qualification failure, not a minor inconvenience. See the section below on what to ask a supplier.

Managing a temperature excursion: quarantine, decision, and documentation

An excursion is any confirmed or suspected departure from the product's required storage temperature range. It does not automatically mean the product is unsafe or ineffective, but it does require a documented assessment before you continue using the stock.

The process on discovering an excursion:

1. Quarantine immediately. Move the affected stock to a clearly labelled quarantine area. Do not use it. Label it "Do Not Use - Under Investigation" with the date and your name.
2. Establish the timeline. Use your temperature logger data to determine when the excursion started, how long it lasted, and the maximum or minimum temperature reached.
3. Contact the manufacturer or your supplying pharmacy. Most manufacturers have a Medical Information line and a documented excursion assessment process. Provide the batch number, the temperature range, and the duration. They will advise whether the product can be released for use or must be destroyed.
4. Document the decision. Record the advice given (in writing if possible), who you spoke to, the date, and the outcome. If the product is to be destroyed, record the destruction method and quantity.
5. Report if appropriate. If a product defect is suspected or if a patient has already been treated with affected stock and experienced an unexpected outcome, report via the MHRA Yellow Card scheme. This is not optional: adverse incident reporting is part of your professional and regulatory obligation.

Do not be tempted to use stock that has been through an unassessed excursion on the basis that it looks normal or the excursion was brief. The manufacturer's assessment is the only valid release decision.

Record keeping and GDP principles for aesthetic clinics

GDP (Good Distribution Practice) is the regulatory framework that governs the storage and distribution of medicinal products in the UK. Aesthetic clinics are not wholesale dealer licence holders, but the principles apply to how you receive, store, and handle stock, and your GPhC-registered supplier operates under these obligations on your behalf.

Minimum records to maintain in clinic:

• Delivery records: supplier, date received, product, batch number, expiry, quantity, condition on receipt.
• Temperature logs: daily min/max (at minimum); continuous logger data strongly preferred.
• Stock movement log: product used per patient (or per session if in a training context), batch number, date.
• Excursion log: all identified excursions, the assessment, and outcome, even if the product was released for use.
• Destruction records: date, product, batch, quantity, method, witness.

Retention period: keep pharmaceutical records for a minimum of five years. This aligns with the standard expected under MHRA GDP guidance and GPhC inspection standards.

Batch traceability is not administrative overhead: if a manufacturer issues a recall, you need to identify within hours whether you hold or have used the affected batch. Without a batch-level treatment record, you cannot do that. See the dermal filler range for products supplied with batch certificates as standard.

What to ask your supplier about their cold chain

Your cold chain is only as strong as your supplier's. Before placing an order for cold-chain products with any pharmacy, ask the following:

• Do you hold an MHRA Wholesale Dealer Authorisation (Human) (WDA(H))? Ask for the licence number and verify it on the MHRA register.
• How are cold-chain products packaged for dispatch? What insulated packaging and coolant system do you use?
• What is your maximum transit time for cold-chain orders and what happens in a delay?
• Do you provide a temperature data logger or indicator with each cold-chain shipment?
• What is your process if a customer reports a suspected excursion on receipt?
• Are your products sourced directly from the UK manufacturer or authorised importer? Can you confirm chain of custody documentation?

A supplier that cannot answer these questions in detail is a supplier you should not be ordering cold-chain injectables from. Longeva Pharmacy operates under MHRA WDA(H) licence 59619 and ships cold-chain products in validated insulated packaging with documented temperature monitoring. If you are not yet registered, apply for a trade account to access the full formulary.

Key takeaways

• Domestic fridges are not acceptable for clinical injectable storage. Use a validated medical refrigerator with alarm functionality.
• Continuous temperature logging is the practical standard. A min/max thermometer alone is not sufficient for GDP-aligned practice.
• The manufacturer IFU is the primary source for storage requirements. It overrides all general guidance.
• Treat every delivery as a documented transfer of responsibility. Check packaging, temperature evidence, and batch details before accepting stock.
• Any suspected excursion requires quarantine, manufacturer assessment, and written documentation before stock is released or destroyed.
• Report adverse outcomes linked to product quality to the MHRA Yellow Card scheme. This is a regulatory and professional obligation.
• Your supplier's cold chain is part of your cold chain. Verify their WDA(H) licence and dispatch process before ordering.

References

• MHRA Good Distribution Practice guidance (GOV.UK)
• MHRA Yellow Card adverse reaction and product defect reporting
• Manufacturer Instructions for Use (IFU): consult the specific IFU supplied with each product for authoritative storage requirements and excursion guidance.

Reviewed for clinical accuracy under the supervision of our Superintendent Pharmacist, Alicia Barker (GPhC 2241860). Longeva Pharmacy is a GPhC-registered pharmacy (registration 9012378) operating under MHRA WDA(H) licence 59619. Information is intended for licensed UK practitioners and does not replace individual clinical judgement.